Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures

被引:68
作者
McDonald, LC
Chen, FJ
Lo, HJ
Yin, HC
Lu, PL
Huang, CH
Chen, P
Lauderdale, TL
Ho, M
机构
[1] Natl Hlth Res Inst, Div Clin Res, Taipei 11529, Taiwan
[2] Cathay Gen Hosp, Taipei, Taiwan
[3] Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan
关键词
D O I
10.1128/AAC.45.11.3084-3091.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A survey of 1,203 Escherichia coli isolates from 44 hospitals in Taiwan revealed that 136 (11.3%) isolates were resistant to fluoroquinolones and that another 261 (21.7%) isolates had reduced susceptibility. Resistance was more common in isolates responsible for hospital-acquired (mostly in intensive care units) infections (17.5%) than in other adult inpatient (11.4%; P = 0.08) and outpatient isolates (11.9%; P > 0.1). Similarly, reduced susceptibility was more common in isolates responsible for hospital-acquired infections (30.9%) than in other adult inpatient (21.0%; P = 0.04) and outpatient (21.4%; P = 0.06) isolates. Isolates from pediatric patients were less likely to be resistant (1.3 versus 12.0%; P < 0.01) but were nearly as likely to have reduced susceptibility (17.7 versus 21.9%; P > 0.1) as nonpediatric isolates. There was an inverse relationship in the proportion of isolates that were resistant versus the proportion that had reduced susceptibility among isolates from individual hospitals (R = 0.031; P < 0.05). In an analysis of isolates from two hospitals, all 9 resistant strains possessed double point mutations in gyrA and all 19 strains with reduced susceptibility strains had single point mutations; no mutations were found among fully susceptible strains. Risk factors for resistance included underlying cancer (odds ratio [OR], 83; 95% confidence interval [CI95], 7.3 to 2,241; P < 0.001), exposure to a quinolone (OR, undefined; P = 0.02), and exposure to a nonquinolone antibiotic (OR, 20; CI95, 2.2 to 482; P < 0.001); underlying cancer was the only independent risk factor (OR, 83; CI95, 8.6 to 807; P < 0.001). There were no significant associations between any of these factors and reduced susceptibility. Whereas acute and chronic quinolone use in cancer patients is a major selective pressure for resistance, other undetermined but distinct selective pressures appear to be more responsible for reduced susceptibility to fluoroquinolones in E. coli.
引用
收藏
页码:3084 / 3091
页数:8
相关论文
共 32 条
[1]   Invasive disease caused by ciprofloxacin-resistant uropathogenic Escherichia coli [J].
Blázquez, R ;
Menasalvas, A ;
Carpena, I ;
Ramírez, C ;
Guerrero, C ;
Moreno, S .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (07) :503-505
[2]   Ciprofloxacin-resistant Escherichia coli emerging in a rehabilitation medical center [J].
Canawati, HN ;
ElFarra, R ;
Seymour, J ;
Shimashita, J ;
Dunn, D ;
Montgomerie, JZ .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1997, 29 (03) :133-138
[3]   EMERGENCE OF QUINOLONE-RESISTANT ESCHERICHIA-COLI BACTEREMIA IN NEUTROPENIC PATIENTS WITH CANCER WHO HAVE RECEIVED PROPHYLACTIC NORFLOXACIN [J].
CARRATALA, J ;
FERNANDEZSEVILLA, A ;
TUBAU, F ;
CALLIS, M ;
GUDIOL, F .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (03) :557-560
[4]   gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli [J].
Conrad, S ;
Oethinger, M ;
Kaifel, K ;
Klotz, G ;
Marre, R ;
Kern, WV .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 38 (03) :443-455
[5]   RISK-FACTORS FOR ACQUISITION OF URINARY-TRACT INFECTIONS CAUSED BY CIPROFLOXACIN RESISTANT ESCHERICHIA-COLI [J].
ENA, J ;
AMADOR, C ;
MARTINEZ, C ;
DELATABLA, VO .
JOURNAL OF UROLOGY, 1995, 153 (01) :117-120
[6]   Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America [J].
Gales, AC ;
Gordon, KA ;
Wilke, WW ;
Pfaller, MA ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (01) :61-64
[7]   Emergence and dissemination of quinolone-resistant Escherichia coli in the community [J].
Garau, J ;
Xercavins, M ;
Rodríguez-Carballeira, M ;
Gómez-Vera, JR ;
Coll, I ;
Vidal, D ;
Llovet, T ;
Ruíz-Bremón, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) :2736-2741
[8]   CDC DEFINITIONS FOR NOSOCOMIAL INFECTIONS, 1988 [J].
GARNER, JS ;
JARVIS, WR ;
EMORI, TG ;
HORAN, TC ;
HUGHES, JM .
AMERICAN JOURNAL OF INFECTION CONTROL, 1988, 16 (03) :128-140
[9]   Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in The Netherlands [J].
Goettsch, W ;
van Pelt, W ;
Nagelkerke, N ;
Hendrix, MGR ;
Buiting, AGM ;
Petit, PL ;
Sabbe, LJM ;
van Griethuysen, AJA ;
de Neeling, AJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (02) :223-228
[10]  
Granlund M, 1996, BRIT J DEV DISABIL, V42, P1